top of page

Search Results

Search results for "InterAx Biotech"

Results found for "InterAx Biotech"

  • Annette Gilchrist: Native Cell Systems, Biased Agonism, and the Pharmacogenomics Gap | Dr. GPCR Ecosystem

    Before returning to academia, she co-founded two GPCR-focused biotechs with Heidi Hamm - CUE Biotech their own detection challenges - became widely used across the field for measuring receptor-G-protein interactions lab - and why the committee said G proteins had already won their Nobel Prize 12:39 Co-founding CUE Biotech So much of the interaction depends on the conformation of the receptor in that particular cell." Annette worked in industry, academia and her entrepreneurial side led her to three companies, Cue Biotech

  • Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems | Dr. GPCR Ecosystem

    around high-affinity, selective fluorescent ligands for GPCRs, supporting researchers working at the interface intelligence, expert-led masterclasses, and structured engagement opportunities for scientists and biotech Expert-led webinars and masterclasses with leading researchers Structured networking for scientists and biotech GPCR membership gives you access to all upcoming live, interactive webinars. Free.

  • YC-Blog (List) | Dr. GPCR Ecosystem

    talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution across biotech

  • Dr. Yamina Berchiche | Dr. GPCR Ecosystem

    GPCR Ecosystem, with the goal is to bring together GPCR scientists, biotech, and pharma leaders as well

  • Revvity | Dr. GPCR Ecosystem

    Elodie Dupuis earned her Master’s degree in biology and biotechnology engineering from the University department, leading her team on the development of innovative HTRF™ and AlphaLISA™ kits for pharma, biotech Mathis holds a biotechnology engineering degree from the National School of Biomolecule Technology of brand recognition for the HTRF technology and accelerate the company’s reagents use in academic labs, biotech serendipity, and partnerships fuel innovation—and how this mindset can transform your research and biotech

  • Dr. Josh Pottel | Dr. GPCR Ecosystem

    More broadly, I hope to be a critical contributor to a growing Canadian biotech sector in both scientific

  • Dr. GPCR Board | Dr. GPCR Ecosystem

    pharmacologist with a ~30 years background in academia and industry, working both in big pharma and biotech at Novo Nordisk A/S allowed me to shape a swiss start-up company from a scientifc idea to a thriving Biotech Trejo has presented her studies at 52 national/international meetings and 66 academic seminars across

  • Dr. Pierre Eftekhari | Dr. GPCR Ecosystem

    Inoviem scientific in Nov. 2011 by myself we have been regularly working with GPCRs for our pharma and biotech

  • GPCR University Group Package | Dr. GPCR Ecosystem

    want to support academic labs with the same high-quality tools, courses, and insights used by leading biotech

  • Dr. Stephane Angers | Dr. GPCR Ecosystem

    led to the development and application of light energy transfer methodology to study protein-protein interaction He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

  • Chris Langmead | Dr. GPCR Ecosystem

    neuroscience R&D program with Servier (France) and is the co-founder and CEO of Phrenix Therapeutics, a biotech Prior to these roles this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology

  • Dr GPCR Ecosystem Feedback | Dr. GPCR Ecosystem

    What challenges do you face most in your research or biotech journey?

  • Sam Hoare: Receptor Residence Time and GPCR Data Analysis | Dr. GPCR Ecosystem

    Hoare now consults for biotech and pharmaceutical clients on GPCR data analysis, receptor binding kinetics As an industry pharmacologist, he consults with numerous pharma and biotechs in understanding and applying

  • Leadership, Impact, and GPCR Signaling with Dr. Michelle Halls | Dr. GPCR Ecosystem

    Join a global GPCR community of scientists and biotech leaders. 👉 Join now Unlock the Full Dr.

  • Model. Predict. Discover. with Dr. Jens Carlsson | Dr. GPCR Ecosystem

    Computational models are moving beyond interpretation into real-world prediction of ligand-receptor interactions Computational chemists and structural biologists Early-career researchers exploring drug discovery Biotech Trained initially as a biotechnology engineer, Jens discovered his true calling during an internship

  • GPCR Pharmacology, Career Twists & Serendipity with Sokhom Pin | Dr. GPCR Ecosystem

    Sokhom Pin shares how he built a biotech career around GPCRs, designed a custom PhD path, and led teams

  • Dr. GPCR Team | Dr. GPCR Ecosystem

    She received her undergraduate degree in Biotechnology from KIIT University in India. his expertise to enhance healthcare outcomes and contribute to the growth of the pharmaceutical and biotech of Pharmaceutical Sciences, Monash University, with a deep interest in understanding drug-receptor interactions

  • 14-Day Trial — Dr. GPCR University | Full Access for $49 | Dr. GPCR Ecosystem

    curated intelligence briefings with expert analysis Community access — connect with scientists and biotech

  • Eurofins DiscoverX | Dr. GPCR | Dr. GPCR Ecosystem

    industry-standard assays, designed for regulatory submissions, are backed by partnerships with leading pharma and biotech backgrounds Multiple Mechanisms of Actions (MOA) cAMP accumulation β-Arrestin recruitment Receptor internalization These assays enable complete pharmacological profiling across cAMP, β-arrestin, and internalization. Internalization profiles distinguishing highly versus weakly internalizing agonists.

  • GPCR Masterclass Live Courses | Dr. GPCR Ecosystem

    Interactive, question-driven, frontier science. designed for GPCR researchers, pharmacologists, and drug discovery scientists working in academia, biotech

  • GPCR Masterclass: Advanced Pharmacology & Drug Discovery | Dr. GPCR

    font_8">Watch Now</p> Bryan Roth GPCR Molecular Glues: Biased Modulation at the Receptor–Transducer Interface Live Masterclass sessions run regularly with interactive Q&A. See what's coming up next. designed for GPCR researchers, pharmacologists, and drug discovery scientists working in academia, biotech

  • Celtarys Research | Dr. GPCR Ecosystem

    focuses on organic synthesis, medicinal chemistry, and the development of GPCR-targeted tools for pharma, biotech adenosine receptor NanoBRET® competitive binding assay enables real-time quantification of ligand–receptor interactions “These tools can dramatically improve how scientists measure ligand-receptor interactions, visualize

  • Terms and Conditions | Dr. GPCR Ecosystem

    is an online platform that provides to (i) individuals and businesses such as scientists, students, biotech others with access to advertise, to promote, and market their services and products related to the biotech Either party in this agreement may seek any interim or preliminary relief from a court of competent jurisdiction

  • GPCR Webinars | Dr. GPCR Ecosystem

    Advanced GPCR webinars for pharmacologists and biotech scientists. Live Q&A. These sessions are designed for interaction — scientists asking direct questions and getting real answers

  • GPCRs and the Science Behind Pain and Recovery with Dr. Alex Serafini | Dr. GPCR Ecosystem

    At one point, he had a job offer at Roivant (a biotech firm known for repurposing shelved compounds),

  • GPCR Assay Strategy, Bias, and Translational Drug Discovery | Dr. GPCR Ecosystem

    GPCR drug discovery, assay innovation, and translational pharmacology bridging academia, pharma, and biotech He trained at the International Centre for Genetic Engineering and Biotechnology in Trieste, then joined in vivo efficacy - Setting a high bar for what counts as true biased agonism - Receptor trafficking, internalization An internal GPCR convention set a demanding standard: a reversal in rank order of potency or efficacy team studied fatty acid conjugated GLP1 agonists that were more biased than semaglutide, with weaker internalization

  • A Brief History of allosteric modulation with Dr. Arthur Christopoulos | Dr. GPCR Ecosystem

    He has received substantial, long-term support from international and national competitive, charitable and commercial sources, as well as being academic co-founder of three GPCR-focussed biotechnology companies Professor Christopoulos has over 360 publications, including in leading international journals such as He has served on the Editorial Board of 8 international journals and was a Councillor of the International his experiences in the pharmaceutical industry, highlighting the differences between big pharma and biotech

  • Dr. Arthur Christopoulos | Dr. GPCR Ecosystem

    He has received substantial, long-term support from international and national competitive, charitable and commercial sources, as well as being academic co-founder of three GPCR-focussed biotechnology companies Professor Christopoulos has over 360 publications, including in leading international journals such as He has served on the Editorial Board of 8 international journals and was a Councillor of the International They also emphasized the significance of fundamental discoveries, the role of biotech, and the need for

  • Dr. John Janetzko | Dr. GPCR Ecosystem

    and John had a detailed discussion about the prospects of staying in academia versus transitioning to biotech

  • Dr. Arthur Christopoulos | Dr. GPCR Ecosystem

    He has received substantial, long-term support from international and national competitive, charitable and commercial sources, as well as being academic co-founder of three GPCR-focussed biotechnology companies Professor Christopoulos has over 360 publications, including in leading international journals such as He has served on the Editorial Board of 8 international journals and was a Councillor of the International They also emphasized the significance of fundamental discoveries, the role of biotech, and the need for

bottom of page